HC Wainwright Reaffirms “Neutral” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Wednesday, February 19th.

60 Degrees Pharmaceuticals Price Performance

NASDAQ SXTP opened at $2.12 on Tuesday. The company has a market capitalization of $15.61 million, a price-to-earnings ratio of -0.21 and a beta of 4.22. 60 Degrees Pharmaceuticals has a 12 month low of $1.78 and a 12 month high of $35.99. The company’s fifty day moving average price is $0.96 and its two-hundred day moving average price is $1.12.

Insider Activity

In related news, CEO Geoffrey S. Dow acquired 35,823 shares of 60 Degrees Pharmaceuticals stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the transaction, the chief executive officer now directly owns 94,580 shares of the company’s stock, valued at $120,116.60. This trade represents a 60.97 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders acquired 60,372 shares of company stock valued at $76,975. Company insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.